Core Viewpoint - The article discusses recent developments in various companies and convertible bonds, highlighting share reduction plans, technology contracts, and new stock listings. Group 1: Share Reduction and Convertible Bonds - The actual controller of Fuchun Dyeing and Weaving and its concerted actors plan to reduce their holdings by no more than 1% of the company's shares [1] - Lu Shan Convertible Bond is subject to strong redemption [1][2] - Song Sheng Convertible Bond will not undergo strong redemption [1][2] - Jiu Qiang Convertible Bond and Yang Feng Convertible Bond will not be adjusted [1][2] Group 2: Technology Contracts and New Listings - Fengshan Group signed a technology development contract with Tsinghua University for sodium-ion battery electrolyte and solid-state lithium-ion battery electrolyte projects [1] - New stocks from Yunhan Chip City and Ruili Kemi are available for subscription on the Shanghai and Shenzhen stock exchanges [1]

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds, "Jiuqiang Convertible Bonds," and will not propose any downward adjustments for the next six months [1] Summary by Relevant Sections - **Board Meeting Decision** - The fifth board meeting of the company on September 18, 2025, approved the proposal not to adjust the conversion price of "Jiuqiang Convertible Bonds" downwards [1] - **Future Conditions** - For the next six months, from September 19, 2025, to March 18, 2026, the company will not propose any downward adjustment even if the conditions for such an adjustment are triggered [1] - The next period for potential adjustment will start from March 19, 2026, which is the first trading day after the non-adjustment period ends [1] - **Future Board Meetings** - If the conditions for downward adjustment are triggered again, the board will convene to decide whether to exercise the right to adjust the conversion price [1]

每经头条（nbdtoutiao）——"25基点太少，50基点太多"：美联储降息"走钢丝"，"特朗普代言人"投下唯 一反对票 （记者 王晓波） 每经AI快讯，九强生物9月18日晚间发布公告称，公司第五届第十八次董事会会议于2025年9月18日在 公司会议室以现场表决和通讯表决相结合的方式召开。会议审议了《关于不向下修正"九强转债"转股价 格的议案》等文件。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

Group 1 - The company, Jiukang Biotechnology, announced that the period for triggering the conversion price adjustment condition starts from August 27, 2025, and ends on September 11, 2025 [1] - During this period, the company's stock has had ten trading days where the closing price was below 85% of the current conversion price, which is 14.43 yuan per share from August 27 to September 4, 2025, and 14.18 yuan per share from September 5, 2025 [1] - If the conversion price adjustment condition is triggered, the company will follow the relevant regulations of the Shenzhen Stock Exchange and the provisions of the prospectus for the issuance of convertible bonds to perform subsequent review procedures and information disclosure obligations [1]

Core Viewpoint - Beijing Jiukang Biotechnology Co., Ltd. announces the suspension of the conversion of its convertible bonds "Jiukang Convertible Bonds" (bond code: 123150) during the rights distribution period from August 28, 2025, to September 4, 2025, and will resume conversion on September 5, 2025 [1] Summary by Relevant Sections - The company guarantees the authenticity, accuracy, and completeness of the information disclosed, ensuring no false records, misleading statements, or significant omissions [1] - The suspension of the bond conversion is in accordance with the regulations outlined in the prospectus for the issuance of convertible bonds to unspecified objects [1] - Bondholders are advised to pay attention to the resumption of conversion on the first trading day after the rights distribution registration date [1]

Core Viewpoint - The report outlines the management of the convertible bond "Jiukang Convertible Bond" issued by Beijing Jiukang Biotechnology Co., Ltd., detailing its issuance, terms, and adjustments to the conversion price due to dividend distributions and share repurchases [3][4][20]. Group 1: Bond Issuance Details - The total issuance amount of the convertible bond is RMB 1.139 billion, with 11,390,000 bonds issued at a face value of RMB 100 each [4][12]. - The bond has a maturity period of 6 years, from June 30, 2022, to June 29, 2028 [5][9]. - The bond's interest rates are structured to increase over the years, starting from 0.3% in the first year to 3.0% in the sixth year [5][9]. Group 2: Conversion Price Adjustments - The initial conversion price was set at RMB 17.63 per share, which was adjusted to RMB 17.53 following a cash dividend distribution [11][12]. - Subsequent adjustments were made to the conversion price due to further cash dividends, resulting in a new conversion price of RMB 17.35 and then RMB 16.95 [15][19]. - The latest adjustment brought the conversion price down to RMB 16.68, effective from September 5, 2025, due to the latest dividend distribution [20]. Group 3: Credit Rating and Management - The bond has been rated AA- by China Chengxin International Credit Rating Co., Ltd., with a stable outlook [9]. - The management of the bond is overseen by China International Capital Corporation, which is responsible for ensuring the interests of bondholders are protected [20].

Core Viewpoint - The company has announced an adjustment to the conversion price of its convertible bonds due to changes in its share capital structure following a cash dividend distribution [1][2][4]. Summary by Sections Conversion Price Adjustment Basis - The adjustment of the conversion price is based on the company's regulations regarding changes in share capital, including stock dividends, capital increases, and cash dividends [1][2]. Reason for Adjustment - The conversion price was adjusted because the company repurchased 3,544,084 shares that did not participate in the cash dividend distribution. The total cash dividend distributed was 174,829,363.20 yuan, calculated based on the number of shares participating in the distribution and the dividend per share of 0.30 yuan [2][3]. Result of Adjustment - The conversion price of the "Jiukang Convertible Bonds" will be adjusted from 16.98 yuan per share to 16.68 yuan per share, effective from September 5, 2025. This adjustment reflects the reduction in the cash dividend per share due to the repurchased shares [4].

Core Points - The company has announced its 2025 semi-annual profit distribution plan, which was approved by the shareholders' meeting and the board of directors [2][3] - The distribution plan involves a cash dividend of RMB 3.00 per 10 shares (including tax), with no capital reserve conversion into additional shares or bonus shares [2][3] - The total cash dividend amount is RMB 174,829,363.20 (including tax) [3] - The record date for the distribution is set for September 4, 2025, and the ex-dividend date is September 5, 2025 [5] - The distribution will not include 3,544,084 shares held in the company's repurchase account [6] - The conversion price for the company's convertible bonds will be adjusted from RMB 16.98 to RMB 16.68 per share effective from September 5, 2025 [6]

Core Viewpoint - Beijing Jiukang Biotechnology Co., Ltd. has announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 3.00 RMB per 10 shares (including tax) without capital reserve conversion or bonus shares [1][3][4]. Group 1: Profit Distribution Plan - The mid-term profit distribution plan has been approved by the company's board of directors and does not require further approval from the shareholders' meeting [2][3]. - The total number of shares eligible for the cash dividend is calculated as the total shares minus those in the company's repurchase account, resulting in 582,764,544 shares eligible for distribution [3][4]. - The total cash dividend to be distributed amounts to 174,829,363.20 RMB (including tax) based on the eligible shares [4][5]. Group 2: Approval Process - The profit distribution plan was discussed and approved during the annual shareholders' meeting held on April 21, 2025, and subsequently by the board of directors on August 26, 2025 [2][3]. - The supervisory board also reviewed and approved the profit distribution plan, confirming it aligns with the company's operational needs and does not harm the interests of shareholders, especially minority shareholders [2][3]. Group 3: Legal and Compliance - The profit distribution plan complies with relevant laws and regulations, including the Company Law of the People's Republic of China and the company's articles of association [4][5]. - The company will issue further announcements regarding the implementation details, including the record date and ex-dividend date [5].

Group 1 - The stock price of Jiukang Bio (300406) closed at 14.81 yuan on July 25, 2025, with an increase of 0.41% and a turnover rate of 2.05% [1] - On July 25, 2025, the net inflow of main funds into Jiukang Bio was 7.4841 million yuan, while retail investors experienced a net outflow of 8.6644 million yuan [2][4] - Jiukang Bio announced the issuance of convertible bonds totaling 1.139 billion yuan, with an initial conversion price set at 17.63 yuan per share [2] Group 2 - The company completed the repurchase and cancellation of 2,017,966 restricted shares, reducing the total share capital to 586,308,628 shares [2][4] - The conversion price of the "Jiukang Convertible Bonds" was adjusted from 16.95 yuan to 16.98 yuan per share, effective from July 23, 2025 [2][4] - CICC stated that the recent actions would not impact the company's daily operations or debt repayment capabilities [2]